Deerfield Management Company, L.P. (Series C) Maxcyte, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $3.95 Billion
- Q1 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Maxcyte, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 19,121 shares of MXCT stock, worth $43,213. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,121Holding current value
$43,213% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding MXCT
# of Institutions
115Shares Held
69.5MCall Options Held
0Put Options Held
0-
Cadian Capital Management, LP New York, NY10MShares$22.7 Million1.17% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$18.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY7MShares$15.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.57MShares$12.6 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$11.4 Million13.13% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $230M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...